Following a robust Q4 earnings beat, IBM's strategic focus on hybrid cloud, AI, and quantum computing earns a price target upgrade from Bank of America, with analysts citing improved growth and free cash flow trajectory.
The historic Farmers' Almanac, famed for its secret weather formula, has been acquired by digital media company Unofficial Networks. The move saves the publication from shuttering, relocates its operations from Maine to New York, and promises a digital-first revival alongside a planned return to print.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
The iconic blue-and-white village of Sidi Bou Said, a jewel of Tunisia's cultural heritage, is grappling with severe landslide risks after unprecedented rainfall. Experts warn that urgent conservation measures are needed to prevent irreversible damage to its historic slopes, as climate change and urban pressure compound the crisis.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
The AI-as-a-Service (AIaaS) market is witnessing significant growth, fueled by cloud innovation and corporate demand for scalable AI solutions. While data privacy remains a hurdle, the integration of generative AI and tailored platforms is accelerating adoption across industries.
Nvidia strengthens its pivotal role in global AI infrastructure through a multi-pronged strategy: securing H200 chip approvals for China, engaging in advanced funding talks with OpenAI, and expanding partnerships with CoreWeave and international research bodies.
Eli Lilly commits $85 million upfront and over $1.8 billion in potential milestones to partner with Repertoire Immune Medicines, aiming to develop a new class of 'tolerizing' therapies that reset the immune system without broad suppression.
FireFly Automatix's AMP-L100 robotic mower has been honored with the Sports Field Management Association's 2026 Innovative Award, signaling a major shift towards AI and automation in turf care. Meanwhile, related EV and materials stocks showed mixed trading activity.
Summit Therapeutics (SMMT) finds itself at a crossroads, with its stock down over 30% in the past year. Conflicting signals from valuation models paint a complex picture: is the biotech firm dramatically overvalued on traditional metrics, or deeply undervalued based on future cash flows?
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.
Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.
The medical technology giant reports double-digit organic sales growth for the fourth consecutive year, driven by its Mako robotic system and strategic leadership shifts, while navigating tariffs and a shifting competitive landscape.
British pharmaceutical giant AstraZeneca has entered a strategic partnership with China's CSPC Pharmaceutical, committing over $1 billion upfront to co-develop next-generation obesity therapies, signaling intensified competition in the lucrative global weight-loss drug market.
As Insmed prepares to unveil key data for its TPIP program at a major medical congress, fresh analyst coverage highlights the treatment's potential to reshape the company's future. Amidst a volatile stock performance, investors are weighing high-growth prospects against persistent financial risks.
